Bill Chiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bill Chiu has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Hiroyuki Shimada
Department of Pathology, Stanford University School of Medicine, Palo Alto, CA
27 shared publications - Bo He
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
21 shared publications - Jiangbin Ye
Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
21 shared publications Claire Abrajano
Division of Pediatric Surgery, Department of Surgery, Stanford University, Palo Alto, USA
20 shared publications- Haowen Jiang
Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
20 shared publications - Yang Li
Department of Radiation Oncology, Stanford University
20 shared publications
Latest Publications
- Open Access
Digital pathological classification of peripheral neuroblastic tumors across multi-continent cohorts
Peripheral neuroblastic tumors (pNTs) are embryonal tumors of neural crest origin with highly variable clinical behaviors, ranging from spontaneous regression to aggressive and fatal disease. The International Neuroblastoma Pathology Classification (INPC) defines four diagnostic categories and stratifies tumors into Favorable Histology (FH) or Unfavorable Histology (UH) group based on age-linked assessment of tumor differentiation/maturation and the Mitosis-Karyorrhexis Index (MKI). Prognostic distinction according to INPC offers significant prediction of clinical outcomes, with patients harboring FH tumors demonstrating longer overall and event-free survival than those with UH tumor. Here, we assembled the largest multi-continental whole-slide histology imaging dataset of pNTs to date, comprising 2,030 tumors from the United States, Canada, Australia, New Zealand, Germany and Japan. Using this dataset, we developed NB-PathAssist, a computational pathology framework for automated INPC-based classification from digitized whole-slide images. NB-PathAssist integrates foundation-model-based feature extraction with an archetype-guided SummaryMixing architecture that compresses whole-slide morphology into representative histologic tokens for tumor-level classification. To automate MKI assessment, we manually annotated 14,049 nuclei, classifying them as mitotic-karyorrhectic (MK) tumor cells, non-MK tumor cells, or non-tumor cells. The resulting model was applied to phenotype cells in whole-slide images across 1,649 tissue sections. Across geographically and institutionally diverse cohorts, NB-PathAssist reproducibly assessed key diagnostic features and generated prognostic classifications concordant with reference INPC annotations. The average balanced accuracy for classifying tumor categories, grade of neuroblastic differentiation, MKI and prognostic groups achieved 0.84, 0.86, 0.89 and 0.96, respectively. We packaged the NB-PathAssist algorithms into an end-to-end online platform for scalable and standardized AI-assisted assessment of pNTs.
Open AccessDigital pathological classification of peripheral neuroblastic tumors across multi-continent cohorts
Peripheral neuroblastic tumors (pNTs) are embryonal tumors of neural crest origin with highly variable clinical behaviors, ranging from spontaneous regression to aggressive and fatal disease. The International Neuroblastoma Pathology Classification (INPC) defines four diagnostic categories and stratifies tumors into Favorable Histology (FH) or Unfavorable Histology (UH) group based on age-linked assessment of tumor differentiation/maturation and the Mitosis-Karyorrhexis Index (MKI). Prognostic distinction according to INPC offers significant prediction of clinical outcomes, with patients harboring FH tumors demonstrating longer overall and event-free survival than those with UH tumor. Here, we assembled the largest multi-continental whole-slide histology imaging dataset of pNTs to date, comprising 2,030 tumors from the United States, Canada, Australia, New Zealand, Germany and Japan. Using this dataset, we developed NB-PathAssist, a computational pathology framework for automated INPC-based classification from digitized whole-slide images. NB-PathAssist integrates foundation-model-based feature extraction with an archetype-guided SummaryMixing architecture that compresses whole-slide morphology into representative histologic tokens for tumor-level classification. To automate MKI assessment, we manually annotated 14,049 nuclei, classifying them as mitotic-karyorrhectic (MK) tumor cells, non-MK tumor cells, or non-tumor cells. The resulting model was applied to phenotype cells in whole-slide images across 1,649 tissue sections. Across geographically and institutionally diverse cohorts, NB-PathAssist reproducibly assessed key diagnostic features and generated prognostic classifications concordant with reference INPC annotations. The average balanced accuracy for classifying tumor categories, grade of neuroblastic differentiation, MKI and prognostic groups achieved 0.84, 0.86, 0.89 and 0.96, respectively. We packaged the NB-PathAssist algorithms into an end-to-end online platform for scalable and standardized AI-assisted assessment of pNTs.
- 12 October 2026
- Published by Springer Nature in Pediatric Surgery International
- Vol. 42 (1) , 434
Neighborhood socioeconomic opportunity and clinical presentation, recurrence, and longitudinal treatment intensity in adolescent pilonidal disease
- 12 October 2026
- Published by Springer Nature in Pediatric Surgery International
- Vol. 42 (1) , 434
Neighborhood socioeconomic opportunity and clinical presentation, recurrence, and longitudinal treatment intensity in adolescent pilonidal disease
- Open Access
- 1 October 2026
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (12) , 163513
Evolution of surgical management in pilonidal disease: A 25-year scoping review and bibliometric analysis of pediatric and adult literature
- 1 October 2026
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (12) , 163513
Open AccessEvolution of surgical management in pilonidal disease: A 25-year scoping review and bibliometric analysis of pediatric and adult literature
- Open Access
- 13 July 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (8) , 3044-3047
Development of cold urticaria after cryotherapy during laser epilation for pilonidal disease: a case report
Introduction: Laser epilation is utilized to reduce pilonidal disease (PD) recurrence and commonly employs cryotherapy for analgesia. Cryotherapy can lead to cold urticaria, particularly in patients with unrecognized cold sensitivity. We report two cases of cold urticaria that developed during laser epilation for PD patients. Case presentation: Case 1: A 14-year-old female with a pilonidal abscess underwent a drainage procedure followed by the Gips procedure and laser epilation. During the initial laser session, she developed urticarial wheals in the area exposed to cryotherapy. The urticaria resolved with oral diphenhydramine. At subsequent laser sessions, analgesia was provided using topical lidocaine. She exhibited no PD symptoms 3 years after treatment. Case 2: A 17-year-old male underwent a drainage procedure for a pilonidal abscess and subsequently underwent the Gips procedure. Laser epilation was initiated, during which he developed urticaria in the area exposed to cryotherapy. After the cessation of laser and cryotherapy, his symptoms resolved spontaneously. Analgesia for subsequent laser sessions was provided using topical lidocaine. He experienced no recurrence of PD at 6 months post-treatment. Discussion: Cold urticaria is triggered by cold exposure and presents with wheals during rewarming. Cold-induced autoallergen and IgE-mediated mast cell degranulation lead to histamine release. Recognition is critical, especially in patients who lack prior cold exposure. Timely antihistamine administration and cold stimuli avoidance can effectively mitigate the symptoms. By comparison, laser-induced urticaria can present hours after laser application and may require corticosteroids for treatment. Conclusion: Cold urticaria can develop after cryotherapy during laser epilation. Awareness, prompt recognition, and the use of alternative analgesia can ensure the safe continuation of laser therapy for PD patients.
- 13 July 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (8) , 3044-3047
Open AccessDevelopment of cold urticaria after cryotherapy during laser epilation for pilonidal disease: a case report
Introduction: Laser epilation is utilized to reduce pilonidal disease (PD) recurrence and commonly employs cryotherapy for analgesia. Cryotherapy can lead to cold urticaria, particularly in patients with unrecognized cold sensitivity. We report two cases of cold urticaria that developed during laser epilation for PD patients. Case presentation: Case 1: A 14-year-old female with a pilonidal abscess underwent a drainage procedure followed by the Gips procedure and laser epilation. During the initial laser session, she developed urticarial wheals in the area exposed to cryotherapy. The urticaria resolved with oral diphenhydramine. At subsequent laser sessions, analgesia was provided using topical lidocaine. She exhibited no PD symptoms 3 years after treatment. Case 2: A 17-year-old male underwent a drainage procedure for a pilonidal abscess and subsequently underwent the Gips procedure. Laser epilation was initiated, during which he developed urticaria in the area exposed to cryotherapy. After the cessation of laser and cryotherapy, his symptoms resolved spontaneously. Analgesia for subsequent laser sessions was provided using topical lidocaine. He experienced no recurrence of PD at 6 months post-treatment. Discussion: Cold urticaria is triggered by cold exposure and presents with wheals during rewarming. Cold-induced autoallergen and IgE-mediated mast cell degranulation lead to histamine release. Recognition is critical, especially in patients who lack prior cold exposure. Timely antihistamine administration and cold stimuli avoidance can effectively mitigate the symptoms. By comparison, laser-induced urticaria can present hours after laser application and may require corticosteroids for treatment. Conclusion: Cold urticaria can develop after cryotherapy during laser epilation. Awareness, prompt recognition, and the use of alternative analgesia can ensure the safe continuation of laser therapy for PD patients.
- 3 April 2026
- Published by Springer Nature in Pediatric Surgery International
- Vol. 42 (1) , 170
Pilonidal pit fibroblasts release cytokines that differ by sex and are altered by estrogen
- 3 April 2026
- Published by Springer Nature in Pediatric Surgery International
- Vol. 42 (1) , 170
Pilonidal pit fibroblasts release cytokines that differ by sex and are altered by estrogen
- Open Access
- 28 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (3) , 322-324
Home intense pulsed light (IPL) device is a useful tool to decrease hair burden in pilonidal patients – a case series
Introduction and Importance: Patients with pilonidal disease (PD) often receive laser epilation to reduce hair burden at the gluteal cleft to decrease symptom recurrence. Laser epilation sessions can be burdensome for patients who need to travel long distance to clinic or are away from home for extended periods of time. In this informal case series, we describe four PD patients who manage epilation with intense pulsed light (IPL) devices at home. Case Presentation: Four PD patients were referred to our Pilonidal Care Clinic and underwent surgical excision. They were all started on regular laser epilation in the clinic. Due to the long travel distance to the clinic, temporary relocating elsewhere, or ease of treatment, they switched to using home IPL for long-term epilation. They reported no injury associated with the IPL use and no recurrence of PD after a follow-up period between 1–3 years. Clinical Discussion: Recurrence of PD symptoms has been shown to decrease with regular laser epilation. However, there is considerable burden in frequent traveling to the clinic to receive laser therapy. Our cases demonstrate that home IPL can be safely used to decrease hair burden in PD and minimize future PD recurrence. Conclusion: IPL devices can serve as an effective and convenient option for epilation at home to prevent PD recurrence.
- 28 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (3) , 322-324
Open AccessHome intense pulsed light (IPL) device is a useful tool to decrease hair burden in pilonidal patients – a case series
Introduction and Importance: Patients with pilonidal disease (PD) often receive laser epilation to reduce hair burden at the gluteal cleft to decrease symptom recurrence. Laser epilation sessions can be burdensome for patients who need to travel long distance to clinic or are away from home for extended periods of time. In this informal case series, we describe four PD patients who manage epilation with intense pulsed light (IPL) devices at home. Case Presentation: Four PD patients were referred to our Pilonidal Care Clinic and underwent surgical excision. They were all started on regular laser epilation in the clinic. Due to the long travel distance to the clinic, temporary relocating elsewhere, or ease of treatment, they switched to using home IPL for long-term epilation. They reported no injury associated with the IPL use and no recurrence of PD after a follow-up period between 1–3 years. Clinical Discussion: Recurrence of PD symptoms has been shown to decrease with regular laser epilation. However, there is considerable burden in frequent traveling to the clinic to receive laser therapy. Our cases demonstrate that home IPL can be safely used to decrease hair burden in PD and minimize future PD recurrence. Conclusion: IPL devices can serve as an effective and convenient option for epilation at home to prevent PD recurrence.
- Open Access
- 7 January 2026
- Published by Elsevier in Journal of Pediatric Surgery Case Reports
- Vol. 126
Pilonidal disease development after initiating testosterone therapy – A case Series
- 7 January 2026
- Published by Elsevier in Journal of Pediatric Surgery Case Reports
- Vol. 126
Open AccessPilonidal disease development after initiating testosterone therapy – A case Series
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Statistical Framework of INPC-Risk Grouping System
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Statistical Framework of INPC-Risk Grouping System
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Purpose:Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC).Experimental Design:The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors.Results:This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC.Conclusions:The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Purpose:Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC).Experimental Design:The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors.Results:This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC.Conclusions:The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
International Neuroblastoma Pathology Classification.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
International Neuroblastoma Pathology Classification.